{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:11:43Z","timestamp":1790687503029,"version":"4.1.0"},"reference-count":114,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The Hedgehog (HH) pathway is a promising therapeutic target in hematological malignancies. Activation of the pathway has been tied to greater chances of relapse and poorer outcomes in several hematological malignancies and inhibiting the pathway has improved outcomes in several clinical trials. One inhibitor targeting the pathway <jats:italic>via<\/jats:italic> the protein Smoothened (SMO), glasdegib, has been approved by the FDA for use with a low dose cytarabine regiment in some high-risk acute myeloid leukemia patients (AML). If further clinical trials in glasdegib produce positive results, there may soon be more general use of HH inhibitors in the treatment of hematological malignancies.While there is clinical evidence that HH inhibitors may improve outcomes and help prevent relapse, a full understanding of any mechanism of action remains elusive. The bulk of AML cells exhibit primary resistance to SMO inhibition (SMOi), leading some to hypothesize that that clinical activity of SMOi is mediated through modulation of self-renewal and chemoresistance in rare cancer stem cells (CSC). Direct evidence that CSC are being targeted in patients by SMOi has proven difficult to produce, and here we present data to support the alternative hypothesis that suggests the clinical benefit observed with SMOi is being mediated through stromal cells in the tumor microenvironment.This paper\u2019s aims are to review the history of the HH pathway in hematopoiesis and hematological malignancy, to highlight the pre-clinical and clinical evidence for its use a therapeutic target, and to explore the evidence for stromal activation of the pathway acting to protect CSCs and enable self-renewal of AML and other diseases. Finally, we highlight gaps in the current data and present hypotheses for new research directions.<\/jats:p>","DOI":"10.3389\/fonc.2022.960943","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T10:38:38Z","timestamp":1661423918000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["The hedgehog pathway in hematopoiesis and hematological malignancy"],"prefix":"10.3389","volume":"12","author":[{"given":"Tucker","family":"Lemos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akil","family":"Merchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/287795a0","article-title":"Mutations affecting segment number and polarity in drosophila","volume":"287","author":"N\u00fcsslein-volhard","year":"1980","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3563490","article-title":"Identification of an amplified, highly expressed gene in a human glioma","volume":"236","author":"Kinzler","year":"1987","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/aja.1001960203","article-title":"Gli, a zinc finger transcription factor and oncogene, is expressed during normal mouse development","volume":"196","author":"Walterhouse","year":"1993","journal-title":"Dev Dyn"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1006\/dbio.1994.1097","article-title":"Expression of three mouse homologs of the drosophila segment polarity gene cubitus interruptus, gli, gli-2, and gli-3, in ectoderm-and mesoderm-derived tissues suggests multiple roles during postimplantation development","volume":"162","author":"Hui","year":"1994","journal-title":"Dev Biol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203282","article-title":"The hedgehog signalling pathway in tumorigenesis and development","volume":"18","author":"Wicking","year":"1999","journal-title":"Oncogene"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0416","article-title":"Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer","volume":"64","author":"Kubo","year":"2004","journal-title":"Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nature02009","article-title":"Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis","volume":"425","author":"Thayer","year":"2003","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.17305\/bjbms.2018.2756","article-title":"The role of the hedgehog signaling pathway in cancer: A comprehensive review","volume":"18","author":"Skoda","year":"2018","journal-title":"Bosnian J Basic Med Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2009.03.007","article-title":"Mechanisms of hedgehog pathway activation in cancer and implications for therapy","volume":"30","author":"Scales","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1242\/dev.128.10.1717","article-title":"Indian Hedgehog activates hematopoiesis and vasculogenesis and can respecifyprospective neurectodermal cell fate in the mouse embryo","volume":"128","author":"Dyer","year":"2001","journal-title":"Development"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1242\/dev.128.22.4523","article-title":"BMP and lhh\/PTHrP signaling interact to coordinate chondrocyte proliferation and differentiation","volume":"128","author":"Minina","year":"2001","journal-title":"Development"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(01)80030-1","article-title":"Schwann cell\u2013derived desert hedgehog controls the development of peripheral nerve sheaths","volume":"23","author":"Parmantier","year":"1999","journal-title":"Neuron"},{"key":"B13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0960-9822(02)00480-3","article-title":"Sertoli cell signaling by desert hedgehog regulates the male germline","volume":"6","author":"Bitgood","year":"1996","journal-title":"Curr Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nature00989","article-title":"Patched acts catalytically to suppress the activity of smoothened","volume":"418","author":"Taipale","year":"2002","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2017.02.015","article-title":"Cholesterol modification of smoothened is required for hedgehog signaling","volume":"66","author":"Xiao","year":"2017","journal-title":"Mol Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.exphem.2016.08.009","article-title":"Primary cilia are present on human blood and bone marrow cells and mediate hedgehog signaling","volume":"44","author":"Singh","year":"2016","journal-title":"Exp Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/384129a0","article-title":"The tumour-suppressor gene patched encodes a candidate receptor for sonic hedgehog","volume":"384","author":"Stone","year":"1996","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/384176a0","article-title":"Biochemical evidence that patched is the hedgehog receptor","volume":"384","author":"Marigo","year":"1996","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)00056-8","article-title":"Hedgehog induces opposite changes in turnover and subcellular localization of patched and smoothened","volume":"102","author":"Denef","year":"2000","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.1139740","article-title":"Patched1 regulates hedgehog signaling at the primary cilium","volume":"317","author":"Rohatgi","year":"2007","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nature04117","article-title":"Vertebrate smoothened functions at the primary cilium","volume":"437","author":"Corbit","year":"2005","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.0010053.eor","article-title":"Gli2 and Gli3 localize to cilia and require the intraflagellar transport protein polaris for processing and function","volume":"1","author":"Haycraft","year":"2005","journal-title":"PLoS Genet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1242\/dev.126.17.3915","article-title":"Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain: Implication of Gli2 and Gli3 as primary mediators of shh signaling","volume":"126","author":"Sasaki","year":"1999","journal-title":"Development"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80678-9","article-title":"Hedgehog-regulated processing of Gli3 produces an anterior\/posterior repressor gradient in the developing vertebrate limb","volume":"100","author":"Wang","year":"2000","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.24.19.8627-8641.2004","article-title":"Suppressor of fused regulates gli activity through a dual binding mechanism","volume":"24","author":"Merchant","year":"2004","journal-title":"Mol Cell Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1242\/dev.052126","article-title":"Suppressor of fused and spop regulate the stability, processing and function of Gli2 and Gli3 full-length activators but not their repressors","volume":"137","author":"Wang","year":"2010","journal-title":"Development"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.14320436.2005.00042.x","article-title":"Negative regulation of Gli1 and Gli2 activator function by suppressor of fused through multiple mechanisms","volume":"73","author":"Barnfield","year":"2005","journal-title":"Differentiation"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1242\/dev.129.20.4753","article-title":"Gli2, but not Gli1, is required for initial shh signaling and ectopic activation of the shh pathway","volume":"129","author":"Bai","year":"2002","journal-title":"Development"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0832317100","article-title":"Transcriptional profiling of the sonic hedgehog response: A critical role for n-myc in proliferation of neuronal precursors","volume":"100","author":"Oliver","year":"2003","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M310589200","article-title":"Transcriptional regulation of bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1","volume":"279","author":"Bigelow","year":"2004","journal-title":"J Biol Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.109.186890","article-title":"Sonic hedgehog induces notch target gene expression in vascular smooth muscle cells via VEGF-a","volume":"29","author":"Morrow","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2010.196","article-title":"Targeting cancer stem cells by inhibiting wnt, notch, and hedgehog pathways","volume":"8","author":"Takebe","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/science.272.5268.1668","article-title":"Human homolog of patched, a candidate gene for the basal cell nevus syndrome","volume":"272","author":"Johnson","year":"1996","journal-title":"Science"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.21.12125","article-title":"A mammalian patched homolog is expressed in target tissues of sonic hedgehog and maps to a region associated with developmental abnormalities","volume":"271","author":"Hahn","year":"1996","journal-title":"J Biol Chem"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0020.1999.283280314.x","article-title":"Nevoid basal cell carcinoma syndrome: Molecular biology and new hypotheses","volume":"28","author":"Cohen","year":"1999","journal-title":"Int J Oral Maxillofac Surg"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/34201","article-title":"Activating smoothened mutations in sporadic basal-cell carcinoma","volume":"391","author":"Xie","year":"1998","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/J.CCELL.2015.02.001","article-title":"Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma","volume":"27","author":"Sharpe","year":"2015","journal-title":"Cancer Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.02.002","article-title":"Smoothened variants explain the majority of drug resistance in basal cell carcinoma","volume":"27","author":"Atwood","year":"2015","journal-title":"Cancer Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718585","article-title":"GLI3 repressor determines hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML","volume":"129","author":"Chaudhry","year":"2017","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/ng916","article-title":"Mutations in SUFU predispose to medulloblastoma","volume":"31","author":"Taylor","year":"2002","journal-title":"Nat Genet"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ydbio.2005.01.008","article-title":"Hedgehog signaling regulates expansion of pancreatic epithelial cells","volume":"280","author":"Kawahira","year":"2005","journal-title":"Dev Biol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/35023008","article-title":"Effects of oncogenic mutations in smoothened and patched can be reversed by cyclopamine","volume":"406","author":"Taipale","year":"2000","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nature01972","article-title":"Widespread requirement for hedgehog ligand stimulation in growth of digestive tract tumours","volume":"425","author":"Berman","year":"2003","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2006.11.033","article-title":"HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity","volume":"17","author":"Clement","year":"2007","journal-title":"Curr Biol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7969286","article-title":"The hedgehog signaling networks in lung cancer: The mechanisms and roles in tumor progression and implications for cancer therapy","volume":"2016","author":"Abe","year":"2016","journal-title":"BioMed Res Int"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nature07275","article-title":"A paracrine requirement for hedgehog signalling in cancer","volume":"455","author":"Yauch","year":"2008","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0813203106","article-title":"Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis","volume":"106","author":"Tian","year":"2009","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0756","article-title":"Paracrine hedgehog signaling in cancer","volume":"69","author":"Theunissen","year":"2009","journal-title":"Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.08.007","article-title":"The stromal niche for epithelial stem cells: A template for regeneration and a brake on malignancy","volume":"32","author":"Roberts","year":"2017","journal-title":"Cancer Cell"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nm1614","article-title":"Essential role of stromally induced hedgehog signaling in b-cell malignancies","volume":"13","author":"Dierks","year":"2007","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5500","article-title":"Stroma-initiated hedgehog signaling takes center stage in b-cell lymphoma","volume":"68","author":"Lindemann","year":"2008","journal-title":"Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611682104","article-title":"Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma","volume":"104","author":"Peacock","year":"2007","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6350","article-title":"Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas","volume":"68","author":"Becher","year":"2008","journal-title":"Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/cancers7030851","article-title":"Hedgehog signaling in the maintenance of cancer stem cells","volume":"7","author":"Cochrane","year":"2015","journal-title":"Cancers"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","first-page":"40361","DOI":"10.1038\/srep40361","article-title":"Targeting the PI3K\/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells","volume":"7","author":"Liang","year":"2017","journal-title":"Sci Rep"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/10780432.CCR-14-1059","article-title":"Expression of hedgehog pathway mediator GLI represents a negative prognostic marker in human acute myeloid leukemia and its inhibition exerts antileukemic effects","volume":"21","author":"Wellbrock","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/84282","article-title":"Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation","volume":"2","author":"Bhardwaj","year":"2001","journal-title":"Nat Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2005.01.010","article-title":"Hedgehog signaling is required for adult blood stem cell formation in zebrafish embryos","volume":"8","author":"Gering","year":"2005","journal-title":"Dev Cell"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0604568103","article-title":"Hedgehog modulates cell cycle regulators in stem cells to control hematopoietic regeneration","volume":"103","author":"Trowbridge","year":"2006","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-241703","article-title":"Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors","volume":"115","author":"Merchant","year":"2010","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.08.003","article-title":"Expansion of bcr-Abl-Positive leukemic stem cells is dependent on hedgehog pathway activation","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2009.03.016","article-title":"Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis","volume":"4","author":"Hofmann","year":"2009","journal-title":"Cell Stem Cell"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2009.03.015","article-title":"Hedgehog signaling is dispensable for adult hematopoietic stem cell function","volume":"4","author":"Gao","year":"2009","journal-title":"Cell Stem Cell"},{"key":"B65","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12967-0150453-9","article-title":"GLI2 inhibition abrogates human leukemia stem cell dormancy","volume":"21","author":"Sadarangani","year":"2015","journal-title":"J Trans Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2009.05.006","article-title":"Smoothening the controversial role of hedgehog in hematopoiesis","volume":"4","author":"Merchant","year":"2009","journal-title":"Cell Stem Cell"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2013.10.010","article-title":"Deciphering hematopoietic stem cells in their niches: a critical appraisal of genetic models, lineage tracing, and imaging strategies","volume":"13","author":"Joseph","year":"2013","journal-title":"Cell Stem Cell"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2008.12.004","article-title":"Wnt-related molecules and signaling pathway equilibrium in hematopoiesis","volume":"4","author":"Malhotra","year":"2009","journal-title":"Cell Stem Cell"},{"key":"B69","doi-asserted-by":"publisher","first-page":"25476","DOI":"10.1038\/srep25476","article-title":"Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia","volume":"6","author":"Irvine","year":"2016","journal-title":"Sci Rep"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1305937110","article-title":"Regulation of human hematopoietic stem cell self-renewal by the microenvironment\u2019s control of retinoic acid signaling","volume":"6","author":"Ghiaur","year":"2013","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3614","article-title":"Human bone marrow niche chemoprotection mediated by cytochrome p450 enzymes","volume":"6","author":"Alonso","year":"2015","journal-title":"Oncotarget"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.139","article-title":"Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? nature reviews","volume":"14","author":"Rosti","year":"2017","journal-title":"Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-038943","article-title":"How I treat chronic myeloid leukemia in the imatinib era","volume":"110","author":"Goldman","year":"2007","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.4161\/15548627.2014.994368","article-title":"Targeting hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABLpositive chronic myeloid leukemia","volume":"11","author":"Zeng","year":"2015","journal-title":"Autophagy"},{"key":"B77","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1182\/blood.v118.21.3535.3535","article-title":"Expression of Gli2, a downstream mediator of the activated hedgehog pathway, represents a negative prognostic marker in AML","volume":"118","author":"Fiedler","year":"2011","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0431-9","article-title":"Hedgehog\/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity","volume":"38","author":"Lau","year":"2019","journal-title":"Oncogene"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2012.36","article-title":"Stromal cells expressing hedgehog-interacting protein regulate the proliferation of myeloid neoplasms","volume":"2","author":"Kobune","year":"2012","journal-title":"Blood Cancer J"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8844","article-title":"Gli-1\/PI3K\/AKT\/NF-kB pathway mediates resistance to radiation and is a target for reversion of responses in refractory acute myeloid leukemia cells","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1023\/B:APPT.0000045801.15585.dd","article-title":"PI3K-akt pathway: Its functions and alterations in human cancer","volume":"9","author":"Osaki","year":"","journal-title":"Apoptosis"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/J.CANLET.2015.11.006","article-title":"Non-canonical GLI1\/2 activation by PI3K\/AKT signaling in renal cell carcinoma: A novel potential therapeutic target","volume":"370","author":"Zhou","year":"2016","journal-title":"Cancer Lett"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1607","article-title":"Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML","volume":"28","author":"Saito","year":"2010","journal-title":"Nat Biotechnol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1182\/blood.v122.21.1649.1649","article-title":"Treatment with hedgehog inhibitor, PF-04449913, attenuates leukemia-initiation potential in acute myeloid leukemia cells","volume":"122","author":"Fukushima","year":"2013","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/nature13283","article-title":"The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation","volume":"511","author":"Zahreddine","year":"2014","journal-title":"Nature"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0666","article-title":"The use of ribavirin as an anticancer therapeutic: Will it go viral","volume":"18","author":"Casaos","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1986","article-title":"Glasdegib with low-dose cytarabine: A new upfront option for the vulnerable AML patient","volume":"25","author":"Fathi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","first-page":"291ra96","DOI":"10.1126\/scitranslmed.aaa5731","article-title":"Integration of hedgehog and mutant FLT3 signaling in myeloid leukemia","volume":"7","author":"Lim","year":"2015","journal-title":"Sci Trans Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16304","article-title":"Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia","volume":"8","author":"Latuske","year":"2017","journal-title":"Oncotarget"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015262","article-title":"Self-renewal of acute lymphocytic leukemia cells is limited by the hedgehog pathway inhibitors cyclopamine and IPI-926","volume":"5","author":"Lin","year":"2010","journal-title":"PLoS One"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-703454","article-title":"Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors","volume":"128","author":"Dagklis","year":"2016","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-873695","article-title":"Activation of hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia","volume":"133","author":"Ghia","year":"2019","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.450","article-title":"Hedgehog\/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia","volume":"34","author":"Kern","year":"2015","journal-title":"Oncogene"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-08-0142","article-title":"Hedgehog-induced survival of b-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target","volume":"6","author":"Hegde","year":"2008","journal-title":"Mol Cancer Res MCR"},{"key":"B96","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1182\/blood-2011-06-359075","article-title":"Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for hedgehog-inhibitor responsiveness in CLL","volume":"119","author":"Decker","year":"2012","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.243","article-title":"Inhibition of GLI, but not smoothened, induces apoptosis in chronic lymphocytic leukemia cells","volume":"29","author":"Desch","year":"2010","journal-title":"Oncogene"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00096-4","article-title":"Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: A phase 1 safety and pharmacokinetics study","volume":"2","author":"Martinelli","year":"2015","journal-title":"Lancet"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13285","article-title":"Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies","volume":"108","author":"Minami","year":"2017","journal-title":"Cancer Sci"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2824","article-title":"Phase ib study of glasdegib, a hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS","volume":"24","author":"Savona","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25238","article-title":"Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results","volume":"93","author":"Cortes","year":"2018","journal-title":"Am J Hematol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"key":"B103","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1182\/blood-2019-124050","article-title":"A phase 1b study of glasdegib in combination with azacitidine in patients with untreated higher-risk myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia","volume":"134","author":"Sekeres","year":"2019","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.4539.4539","article-title":"Dasatinib plus smoothened (SMO) inhibitor BMS-833923 in chronic myeloid leukemia (CML) with resistance or suboptimal response to a prior tyrosine kinase inhibitor (TKI): Phase I study CA180323","volume":"124","author":"Shah","year":"2014","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1182\/blood.v128.22.3174.3174","article-title":"Phase 2 trial of smoothened (SMO) inhibitor PF-04449913 (PF-04) in refractory myelodysplastic syndromes (MDS)","volume":"128","author":"Lancet","year":"2016","journal-title":"Blood"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.7111","article-title":"A phase 2 study of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis","volume":"32","author":"Sasaki","year":"2014","journal-title":"J Clin Oncol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13045-018-0661-x","article-title":"A phase ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis","volume":"11","author":"Couban","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.1347.1347","article-title":"Phase I\/IB study of azacitidine and hedgehog pathway inhibition in myeloid malignancies","volume":"126","author":"Tibes","year":"2015","journal-title":"Blood"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1956","article-title":"U.S. food and drug administration approval: Vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma","volume":"19","author":"Axelson","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2051","article-title":"FDA Approval summary: Sonidegib for locally advanced basal cell carcinoma","volume":"23","author":"Casey","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0365","article-title":"FDA Approval summary: Glasdegib for newly diagnosed acute myeloid leukemia","volume":"25","author":"Norsworthy","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1021\/ml2002423","article-title":"Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened","volume":"3","author":"Munchhof","year":"2012","journal-title":"ACS Med Chem Lett"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8500","article-title":"Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system","volume":"29","author":"R\u00f6llig","year":"2011","journal-title":"J Clin Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.187","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia","volume":"31","author":"Godwin","year":"2017","journal-title":"Leukemia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.960943\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T10:38:42Z","timestamp":1661423922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.960943\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":114,"alternative-id":["10.3389\/fonc.2022.960943"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.960943","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]},"article-number":"960943"}}